For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for profitable short-term investing, highlighting that trends can reverse unexpectedly, leading to potential losses for investors [1][2]. Group 1: Stock Performance - Corcept Therapeutics (CORT) has shown a solid price increase of 56.7% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - CORT has also experienced an 11% price increase over the last four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 82% of its 52-week high-low range, indicating it may be on the verge of a breakout [5]. Group 2: Fundamental Strength - CORT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like CORT that are on an uptrend supported by strong fundamentals [3]. - It mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [8].

Industry Overview - The drug industry is anticipating a shift in policy with Donald Trump's reelection, potentially leading to increased innovation and M&A activity, while efforts to repeal the Inflation Reduction Act (IRA) are likely [1][2] - Drug pricing reforms will remain a priority for the new government, with previous emphasis on controlling drug prices during Trump's last term [2] - The Zacks Medical-Drugs industry is showing promising trends in 2024, driven by increased M&A and positive pipeline developments, particularly in diabetes/obesity, inflammation, and neuroscience [3] Company Highlights - **Corcept Therapeutics**: The company’s sole marketed drug, Korlym, has seen strong demand, leading to an increase in annual revenue guidance. The stock has risen 67.2% this year, with 2024 earnings estimates increasing from $1.12 to $1.31 per share [15][16] - **Madrigal Pharmaceuticals**: The FDA approved Rezdiffra, the first therapy for noncirrhotic NASH, generating approximately $77 million in sales since its launch. The stock is up 53.4% this year, with loss estimates improving from $29.49 to $24.08 per share [17][18] - **Catalyst Pharmaceuticals**: The lead drug Firdapse is experiencing strong demand, and the company has diversified its portfolio with the acquisition of Fycompa. The stock has risen 38.3% this year, with stable earnings estimates at $1.92 per share [19][20] - **Theravance Biopharma**: The company is benefiting from increased collaboration revenues from its product Yupelri. However, the stock has declined 22.1% this year, with stable loss estimates at 45 cents per share [21][23] - **Larimar Therapeutics**: The company is developing nomlabofusp for Friedreich's ataxia, with a significant stock increase of 100.5% over the past year. Loss estimates have narrowed from $1.39 to $1.16 per share [24][26] Market Performance - The Zacks Medical-Drugs industry has underperformed the S&P 500 and the broader Medical sector, with a year-to-date decline of 3.4% compared to the S&P 500's increase of 24.7% [13] - The industry currently trades at a price-to-sales ratio of 2.24, significantly lower than the S&P 500's 6.19 and the Zacks Medical sector's 3.44 [14]

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely. However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his pr ...

Corcept Therapeutics Incorporated (CORT) has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024.This company engages in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic and neurologic disorders in the United States. It has spent more than 25 years dedicated to advancing cortisol modulation, resulting in the discovery of more than 1,000 unique selective modulators. Remaining focused on innovation, Corcept i ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 5th:Corcept Therapeutics Incorporated (CORT) : This drugmaker for severe endocrinologic, oncologic, metabolic, and neurologic disorders has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.6% over the last 60 days.Corcept’s shares gained 46.4% over the last three months compared with the S&P 500’s advance of 9.1%. The company possesses a Mome ...